NCT02011334已完成3 期
A MULTICENTER, OPEN LABEL STUDY TO EVALUATE EFFICACY AND SAFETY OF TOCILIZUMAB GIVEN SUBCUTANEOUSLY IN MONOTHERAPY AND IN COMBINATION WITH NON-BIOLOGIC DMARDS IN PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN LATIN AMERICA
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 285
- 主要终点
- Efficacy: Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) Remission Rate
研究概览
简要总结
This multi-center, open-label, single-arm, Phase IIIb study will evaluate the safety and efficacy of subcutaneous RoActemra/Actemra alone or in combination with non-biologic disease modifying antirheumatic drugs (DMARDs) in rheumatoid arthritis patients in Latin America with an inadequate response to non-biologic DMARDs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients >/= 18 years of age.
- •Patients with a diagnosis of active RA according to the revised (1987) ACR criteria or EULAR/ACR (2010) criteria.
- •Patients with moderate to severe RA (DAS-ESR 28 >/= 3.2).
- •Receiving non-study treatment on an outpatient basis.
- •Oral corticosteroids (</= 10 mg/day prednisone or equivalent), NSAIDs and non-biologic DMARDs are permitted if on a stable dose regimen for >/= 4 weeks prior to Baseline.
- •Inadequate response to previous non-biologic DMARD therapy.
- •Use of effective contraception throughout the study as defined by protocol; female patients of childbearing potential cannot be pregnant.
排除标准
- •Presence of clinically significant medical conditions.
- •History of diverticulitis, diverticulosis requiring antibiotic treatment, or chronic ulcerative lower GI disease that might predispose to perforation.
- •Current or history of recurrent bacterial, viral, fungal, mycobacterial, or other infections.
- •Any infection requiring hospitalization or treatment with IV antibiotics within 4 weeks of Screening or oral antibiotics within 2 weeks of Screening.
- •Clinically significant findings on lab tests and/or hepatits B or C, or HIV screenings.
- •Active TB requiring treatment within the previous 3 years.
- •Evidence of active malignant disease, malignancies diagnosed within the previous 10 years, or breast cancer diagnosed within the previous 20 years.
- •History of alcohol, drug, or chemical abuse within 1 year prior to Screening.
- •Neuropathies or other conditions that might interfere with pain evaluation.
- •Major surgery (including joint surgery) within 8 weeks prior to Screening or planned major surgery within 6 months following Baseline.
- •Rheumatic autoimmune disease other than RA, including systemic lupus erythematosis, mixed connective tissue disorder, scleroderma, polymyositis, or significant systemic involvement secondary to RA (e.g., vasculitis, pulmonary fibrosis or Felty's syndrome). Secondary Sjögren's syndrome with RA is permitted.
- •Functional Class IV as defined by the ACR Classification of Functional Status in-Rheumatoid Arthritis (Appendix 2).
- •Diagnosis of juvenile idiopathic arthritis or juvenile RA, and/or RA before the age of
- •Prior history of or current inflammatory joint disease other than RA.
- •Previous exposure to RoActemra/Actemra (either IV or SC).
- •Prior treatment with a biologic agent.
- •Treatment with any investigational agent within 4 weeks (or five half-lives of the investigational drug, whichever is longer) of Screening.
- •Previous treatment with any cell-depleting therapies, including investigational agents or approved therapies, with alkylating agents such as chlorambucil, or with total lymphoid irradiation.
- •Treatment with IV gamma globulin, plasmapheresis within 6 months of Baseline.
- •Immunization with a live/attenuated vaccine within 4 weeks prior to Baseline.
研究组 & 干预措施
RoActemra/Actemra
Experimental
干预措施: tocilizumab [RoActemra/Actemra] (Drug)
结局指标
主要结局
Efficacy: Disease Activity Score 28-erythrocyte sedimentation rate (DAS28-ESR) Remission Rate
时间窗: 24 weeks
次要结局
- Safety: Incidence of adverse events (AE)(60 weeks)
- Efficacy: Change in DAS28-ESR(From baseline to Week 52)
- Efficacy: ACR/EULAR responses(52 weeks)
- Efficacy: Change in joint swelling/tenderness (SJC/TJC)(From baseline to Week 52)
- Efficacy: Change in disease activity (CDAI/SDAI)(From baseline to Week 52)
- Safety: Assessment of immunogenicity(60 weeks)
- Patient-reported outcomes(60 weeks)
- Efficacy: DAS28-ESR Remission Rate(52 weeks)
- Efficacy: Proportion of patients who maintain DAS28 Remission/LDA(From Week 24 to Week 52)
- Safety: Rates of AE leading to dose modification or study withdrawal(52 weeks)
- Safety: Assessment of physical examination and vital signs(52 weeks)
- Safety: Incidence of clinically significant laboratory abnormalities following treatment(52 weeks)
研究者
相似试验
已完成
3 期
Eculizumab in Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH) in ChinaParoxysmal Nocturnal HemoglobinuriaNCT05886244Alexion Pharmaceuticals, Inc.25
已完成
3 期
A Study of Subcutaneous Tocilizumab as Monotherapy and/or in Combination With Non-Biologic Disease Modifying Anti-Rheumatic Drugs (DMARDs) in Participants With Rheumatoid ArthritisRheumatoid ArthritisNCT01941095Hoffmann-La Roche100
已完成
3 期
4EVER - Efficacy, Safety, Health Economics, Translational Research of Postmenopausal Women With Estrogen Receptor Positive Locally Advanced or Metastatic Breast CancerMetastatic Breast CancerNCT01626222Novartis Pharmaceuticals301
已完成
3 期
To Study Clinical Effectiveness and Safety of Olaparib Monotherapy in Metastatic Breast Cancer Patients.HER2-ve Metastatic Breast CancerGermline BRCA1/2 MutationsSomatic BRCA1/2 MutationsNCT03286842AstraZeneca256
Unknown
3 期
A Study of Amphotericin B Liposome for Injection in Patients With Persistent Neutropenia and FeverNeutropenia and FeverNCT05108545CSPC ZhongQi Pharmaceutical Technology Co., Ltd.93